Banco BTG Pactual S.A. Makes New $576,000 Investment in Insmed Incorporated (NASDAQ:INSM)

Banco BTG Pactual S.A. acquired a new stake in shares of Insmed Incorporated (NASDAQ:INSM) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,240 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

Several other hedge funds have also made changes to their positions in the stock. Steward Partners Investment Advisory LLC raised its holdings in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC lifted its position in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the period. Spire Wealth Management acquired a new stake in Insmed during the fourth quarter worth $47,000. Smartleaf Asset Management LLC increased its holdings in Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares during the period. Finally, Venturi Wealth Management LLC acquired a new position in shares of Insmed in the 4th quarter valued at $86,000.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the transaction, the insider now directly owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 550,957 shares of company stock worth $42,992,528. 4.60% of the stock is currently owned by company insiders.

Insmed Price Performance

INSM opened at $78.54 on Wednesday. The company has a fifty day moving average price of $77.84 and a two-hundred day moving average price of $73.89. The firm has a market capitalization of $14.22 billion, a PE ratio of -14.05 and a beta of 1.28. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Bank of America upped their price target on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Truist Financial raised their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.